

## Pharmacy Medical Necessity Guidelines: Neupro® (rotigotine)

Effective: April 14, 2020

Prior Authorization Required	√	Type of Review – Care Management	
Not Covered		Type of Review – Clinical Review	√
Pharmacy (RX) or Medical (MED) Benefit	RX	Department to Review	RXUM
<p>These pharmacy medical necessity guidelines apply to the following:</p> <p><b>Commercial Products</b></p> <input type="checkbox"/> Tufts Health Plan Commercial products – large group plans <input type="checkbox"/> Tufts Health Plan Commercial products – small group and individual plans <input type="checkbox"/> Tufts Health Freedom Plan products – large group plans <input type="checkbox"/> Tufts Health Freedom Plan products – small group plans <ul style="list-style-type: none"> <li>CareLink<sup>SM</sup> – Refer to CareLink Procedures, Services and Items Requiring Prior Authorization</li> </ul> <p><b>Tufts Health Public Plans Products</b></p> <input type="checkbox"/> Tufts Health Direct – A Massachusetts Qualified Health Plan (QHP) (a commercial product) <input checked="" type="checkbox"/> Tufts Health Together – MassHealth MCO Plan and Accountable Care Partnership Plans <input type="checkbox"/> Tufts Health RITogether – A Rhode Island Medicaid Plan		<p><b>Fax Numbers:</b>  RXUM:  617.673.0988</p>	

**Note:** This guideline does not apply to Medicare Members (includes dual eligible Members).

### OVERVIEW

#### FDA-APPROVED INDICATIONS

Neupro® (rotigotine transdermal system) is a dopamine agonist indicated for the treatment of signs and symptoms of idiopathic Parkinson’s disease and for the treatment of moderate-to-severe primary Restless Legs Syndrome.

### COVERAGE GUIDELINES

The plan may authorize coverage of Neupro® (rotigotine) for Members when **all** of the following criteria for a particular regimen are met and limitations do not apply:

#### For the diagnosis of Parkinson’s disease

- The Member failed a course of therapy with at least one oral dopamine agonist agent (e.g., ropinirole, pramipexole), or the provider indicates therapy with the oral agents is clinically inappropriate

OR

#### For the diagnosis of restless leg syndrome

- The Member failed a course of therapy with the at least one oral dopamine agonist agent, (e.g., ropinirole or pramipexole), or the provider indicates therapy with the oral agents is clinically inappropriate

### LIMITATIONS

- The quantity is limited to one transdermal patch per day.

### CODES

None

### REFERENCES

- Neupro (rotigotine transdermal system) [prescribing information]. Smyrna, GA: UCB, Inc; January 2019.

### APPROVAL HISTORY

March 14, 2013: Reviewed by Pharmacy & Therapeutics Committee.

Subsequent endorsement date(s) and changes made:

- November 4, 2014: Approval duration changed to one year.
- September 16, 2015: Approval duration modified to life of plan.
- January 1, 2016: Administrative change to rebranded template.
- September 13, 2016: No changes.
- May 9, 2017: Administrative update, Adding Tufts Health RITogether to the template
- September 12, 2017: No changes.

7. October 16, 2018: Administrative update to template.
8. April 9, 2019: No changes.
9. June 11, 2019: Updated criteria to allow trial and failure with one prerequisite drug and not two.
10. April 14, 2020: No changes.

#### **BACKGROUND, PRODUCT AND DISCLAIMER INFORMATION**

Pharmacy Medical Necessity Guidelines have been developed for determining coverage for plan benefits and are published to provide a better understanding of the basis upon which coverage decisions are made. The plan makes coverage decisions on a case-by-case basis considering the individual member's health care needs. Pharmacy Medical Necessity Guidelines are developed for selected therapeutic classes or drugs found to be safe, but proven to be effective in a limited, defined population of patients or clinical circumstances. They include concise clinical coverage criteria based on current literature review, consultation with practicing physicians in the service area who are medical experts in the particular field, FDA and other government agency policies, and standards adopted by national accreditation organizations. The plan revises and updates Pharmacy Medical Necessity Guidelines annually, or more frequently if new evidence becomes available that suggests needed revisions.

For self-insured plans, coverage may vary depending on the terms of the benefit document. If a discrepancy exists between a Pharmacy Medical Necessity Guideline and a self-insured Member's benefit document, the provisions of the benefit document will govern.

Treating providers are solely responsible for the medical advice and treatment of members. The use of this policy is not a guarantee of payment or a final prediction of how specific claim(s) will be adjudicated. Claims payment is subject to member eligibility and benefits on the date of service, coordination of benefits, referral/authorization and utilization management guidelines when applicable, and adherence to plan policies and procedures and claims editing logic.